Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + Lenvatinib or Sorafenib vs Lenvatinib or Sorafenib in HCC
NCT04770896Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Apr 2021
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies
- Countries
- 28
01
Overview
A Phase 3 trial of atezolizumab in hepatocellular carcinoma (HCC), sponsored by Roche. Started Apr 2021; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04770896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04770896.